Literature DB >> 11771753

Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation.

B Lubec1, B C Yoo, M Dierssen, N Balic, G Lubec.   

Abstract

Information on the fetal brain in Down syndrome (DS) is limited. In particular, there is no systematic study available on cholinergic, monoaminergic or serotoninergic innervation in the early second trimester. It was therefore the aim of the study to investigate whether deficits of any of these systems known to occur in adults with DS, was present at this early phase. For this purpose we determined markers for neuronal density (neuron-specific enolase, NSE), for cholinergic innervation (vesicular acetylcholine transporter, VAChT), for monoaminergic innervation (vesicular monoamine transporter 2, VMAT2; tyrosine hydroxylase, TH) and for the serotoninergic system (serotonine transporter, SERT) in brain of control and DS fetuses in the early second trimester using immunoblotting. Values for all neurotransmission systems were measurable at this time point of human development and comparable in control and DS fetuses. We conclude that during the second trimester DS patients do not differ in terms of immunoreactivity for all markers studied. This first study on that subject warrants further investigations for the determination of the time point when neurotransmitter deficits in DS brain are starting, a hallmark most important for pathogenesis and pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771753     DOI: 10.1007/978-3-7091-6262-0_25

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

1.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

Review 2.  The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.

Authors:  Sonia Do Carmo; Benjamin Kannel; A Claudio Cuello
Journal:  Cells       Date:  2021-12-22       Impact factor: 6.600

3.  Genome-wide expression analysis in Down syndrome: insight into immunodeficiency.

Authors:  Chong Li; Lei Jin; Yun Bai; Qimin Chen; Lijun Fu; Minjun Yang; Huasheng Xiao; Guoping Zhao; Shengyue Wang
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.